{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["26(3)"],"submitter":["Lee HE"],"pubmed_abstract":["<h4>Purpose</h4>This study investigated functional outcomes in lower urinary tract symptoms (LUTS), the incidence of incidental prostate cancer (PCa), and changes in prostate-specific antigen (PSA) levels after holmium laser enucleation of the prostate (HoLEP) in patients with elevated PSA and benign prostatic hyperplasia (BPH).<h4>Methods</h4>A retrospective review of a prospectively designed protocol for patients who underwent HoLEP at our institution from January 2010 to May 2020 was conducted. Patients were classified into low-PSA (<3.0 ng/mL) and high-PSA (≥3.0 ng/mL) groups at baseline. Follow-up for PSA was performed at the sixth postoperative month. Baseline and postoperative clinical parameters, functional parameters, PCa incidence, and postoperative changes in PSA were compared b"],"journal":["International neurourology journal"],"pagination":["248-257"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9537433"],"repository":["biostudies-literature"],"pubmed_title":["Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate."],"pmcid":["PMC9537433"],"pubmed_authors":["Kim B","Yoon HS","Oh SJ","Suh J","Lee HE"],"additional_accession":[]},"is_claimable":false,"name":"Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate.","description":"<h4>Purpose</h4>This study investigated functional outcomes in lower urinary tract symptoms (LUTS), the incidence of incidental prostate cancer (PCa), and changes in prostate-specific antigen (PSA) levels after holmium laser enucleation of the prostate (HoLEP) in patients with elevated PSA and benign prostatic hyperplasia (BPH).<h4>Methods</h4>A retrospective review of a prospectively designed protocol for patients who underwent HoLEP at our institution from January 2010 to May 2020 was conducted. Patients were classified into low-PSA (<3.0 ng/mL) and high-PSA (≥3.0 ng/mL) groups at baseline. Follow-up for PSA was performed at the sixth postoperative month. Baseline and postoperative clinical parameters, functional parameters, PCa incidence, and postoperative changes in PSA were compared b","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-19T04:49:19.579Z","creation":"2025-04-19T04:49:19.579Z"},"accession":"S-EPMC9537433","cross_references":{"pubmed":["36203257"],"doi":["10.5213/inj.2244176.088"]}}